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Abstract
Background: In the quest for public and private resources, prevention continues to face a difficult
challenge in obtaining tangible public and political support. This may be partly because the economic
evidence in favour of prevention is often said to be largely missing. The overall aim of this paper is
to examine whether economic evidence in favour of prevention does exist, and if so, what its main
characteristics, weaknesses and strengths are. We concentrate on the evidence regarding primary
prevention that targets cardiovascular disease event or risk reduction.
Methods: We conducted a systematic literature review of journal articles published during the
period 1995–2005, based on a comprehensive key-word based search in generic and specialized
electronic databases, accompanied by manual searches of expert databases. The search strategy
consisted of combinations of freetext and keywords related to economic evaluation, cardiovascular
diseases, and primary preventive interventions of risk assessment or modification.
Results: A total of 195 studies fulfilled all of the relevant inclusion criteria. Overall, a significant
amount of relevant economic evidence in favour of prevention does exist, despite important
remaining gaps. The majority of studies were cost-effectiveness-analyses, expressing benefits as "life
years gained", were conducted in a US or UK setting, assessed clinical prevention, mainly drugs
targeted at lowering lipid levels, and referred to subjects aged 35–64 years old with at least one
risk factor.
Conclusion: First, this review has demonstrated the obvious lack of economic evaluations of
broader health promotion interventions, when compared to clinical prevention. Second, the clear
role for government to engage more actively in the economic evaluation of prevention has become
very obvious, namely, to fill the gap left by private industry in terms of the evaluation of broader
public health interventions and regarding clinical prevention, in light of the documented relationship
between study funding and reporting of favourable results. Third, the value of greater adherence
to established guidelines on economic evaluation cannot be emphasised enough. Finally, there
appear to be certain methodological features in the practice of economic evaluations that might
bias the choice between prevention and cure in favour of the latter.
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Background
In the quest for public and private resources, prevention
continues to face a difficult challenge in obtaining tangi-
ble public and political support. In part this is because
contrary to curative care, prevention has no identifiable
beneficiaries and is commonly characterised by immedi-
ate costs and delayed benefits. In addition – and this has
been the basic motivation for this study – the economic
evidence in favour of prevention is said to be largely miss-
ing [1,2]. The purpose of this article is to examine the
main characteristics, weaknesses and strengths of the
existing evidence regarding economic evaluations of pri-
mary prevention, i.e., the prevention of disease before it
occurs for the first time, including health promotion,
screening for risk factors and risk factor modification
through clinical prevention efforts. We concentrate on the
evidence regarding primary prevention targeting cardio-
vascular disease (CVD) event or risk reduction. CVD
accounts for the largest share of mortality in most high-
income countries, and increasingly also in developing
countries [3]. By focusing on CVD prevention we are also
able to capture a set of the risk factors that account for the
largest share of the disease burden in Europe, such as
tobacco consumption, high blood pressure, high body
mass index, and physical inactivity.
Based on empirical analyses of the published literature,
we describe and summarize the quantity, content and
type of existing health economic evidence in relation to
diseases, interventions and health care systems that has
been generated so far. These results should also provide
indications as for areas in which evidence is particularly
scarce or even absent. To allow for both a comprehensive
overview and more in depth analysis, the review is divided
in two parts:
1) In a first step, we identified all full economic analyses
that evaluated primary prevention activities aiming at
reducing the burden of cardiovascular diseases. These
evaluations were assessed in terms of various key parame-
ters that allow us to illustrate and quantify the published
evidence, to describe interventions and preventive strate-
gies that have been intensively evaluated, and finally to
draw conclusions on areas that have been outside
researchers' focus so far. This part of the study thus gener-
ates data about the basic characteristics of all identified
economic evaluations conducted in the area of primary
prevention of cardiovascular disease.
2) In the second step, we concentrate on a subsample of
studies to conduct an in-depth analysis of economic eval-
uations of interventions targeted at specific risk factors for
cardiovascular diseases. We selected dietary intake, weight
management and physical activity as major targets for risk
reduction. This focus has been set because these are the
main proximate drivers of obesity, no doubt a key public
health challenge that has been less researched than, for
instance, smoking and excessive alcohol consumption.
We did not select any particular type of primary preventive
interventions, so that this second part of the study should
depict the available evidence on the entire continuum of
primary prevention: public health policy, health promo-
tion, and clinical prevention. While the subsample is cer-
tainly not representative of all economic evaluations
assessed in phase 1 of our study, we expected to detect cer-
tain methodological and systematic problems and key
questions that may be relevant to the majority of evalua-
tions of primary prevention activities, irrespective of the
particular intervention under study.
Methods
Literature search and study selection
We searched the databases Embase, Pubmed (Medline),
NHS-Pharmline, NHS EED, and OHE HEED for relevant
articles. In addition, the Harvard cost-effectiveness registry
was manually searched. The searches were conducted in
May 2006. We also consulted a database of German eco-
nomic evaluations published in 1990–2004 that was the
result of a prior study focusing on the German health care
system [4]. The search strategy consisted of combinations
of freetext and MeSH ("Medical subject heading") terms
related to economic evaluation, cardiovascular diseases,
and primary prevention interventions for risk assessment
or modification (see Appendix 1). "Wild cards" and
abbreviations of terms were used. The retrieved records
were further refined for the relevant year range and, where
available, limited to journal articles. Studies were
included in the review when they fulfilled all of the inclu-
sion criteria listed in Table 1.
Data extraction and critical appraisal
The identified articles were retrieved as fulltexts. We devel-
oped a checklist comparable to that used by other
researchers to extract data alongside review of the original
studies. The following data were extracted from all
included economic evaluations (study phase 1):
- the publication language
- the country of origin/investigated health care system
- the study design (randomized clinical trial, observa-
tional study, modelling, or combination of trial and mod-
elling)
- the type of economic evaluation (cost-effectiveness anal-
ysis, cost-utility analysis, cost-benefit analysis, cost-mini-
mization analysis, cost-consequence analysis)
- the intervention target (targeted risk factors)Cost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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- the target population in terms of age, gender, risk factors
- the type of primary prevention intervention (health pro-
motion, i.e., addressing a community of people; screen-
ing, i.e., identification persons at higher risk for a disease;
clinical prevention, i.e., individually delivered to a certain
patient)
- the benefit measures: natural units (extracted in detail),
life years gained, QALYs (DALYs), Willingness to pay
(benefit in monetary terms)
- the study perspective (as stated by authors)
- the funding of the study (as stated by authors)
The data extraction form did not include explicit quality
ratings. For all studies, we used only the information pro-
vided in the original publication. Each paper was inde-
pendently read by a single, trained researcher. After critical
appraisal, information collected in data extraction forms
were transferred to an electronic database. Based on this
initial step of the systematic review, we identified the sub-
collection of evaluations that assessed the economics of
primary prevention interventions targeted at dietary
intake, weight management, or physical activity. These
studies were the objective of our in-depth analyses. Each
paper in the subsample was independently read by two
trained researchers. In addition to those criteria already
extracted in phase 1, we closely followed guidelines on
economic evaluations and selected additional key aspects
according to which the study-specific information was
disaggregated [5,6].
These included:
- The specific intervention under study
- the comparator against which the interventions was eval-
uated
- the target group
- the time horizon
- the kind of discounting (rate and base year)
- the cost components included, the incremental cost-
effectiveness ratio (ICER)
- the methods employed to handle uncertainty, and
- the consideration of future costs.
For each of the studies included in phase 2, case reports
were written that summarized the basic objective, meth-
odology, and results of the evaluations as well as underly-
ing key assumptions.
Data analysis
Descriptive statistics were used to analyze the main char-
acteristics of the included economic evaluations and to
examine associations between extracted categories, e.g.,
type of intervention and target group. To assess potential
developments over time, we split the overall period cov-
ered into 1995–2000 and 2001–2005. Comparisons were
made using chi-square tests. A p-value of less than 0.05
was considered significant. All analyses were performed
using STATA 9 software [7].
Results
The systematic literature search initially identified 5,482
candidate articles, of which 584 were selected for fulltext
retrieval (figure 1). The majority of articles were discarded
at this initial stage mainly because they were duplicates (n
= 3,218), or it was obvious from the bibliographic data
and abstract that they violated basic inclusion criteria
(e.g., abstracts in congress supplements) (n = 1,680). Of
the 584 fulltexts selected for retrieval, a further 389 were
dropped after the critical appraisal because they failed one
or more inclusion criteria. Most studies were excluded
Table 1: Inclusion criteria
Contentual features:
■  Studies evaluating primary prevention activities targeted at cardiovascular event or risk reduction, i.e., prevention of the disease before it 
occurs for the first time;
■  Objective: Screening for and modification of risk factors for primary cardiovascular events;
■  Population: Persons at increased risk but without evidence of cardiovascular disease;
■  Endpoints: Cardiovascular outcomes/events or modified risk factor;
Formal features:
■  Full economic evaluation, i.e., comparative analysis of costs and outcomes of at least two alternatives;
■  Applied study (trial generating primary data or modelling of secondary data). Methodological and general articles, letters and abstracts were 
excluded;
■  Assessment of, or application to the US, Canadian or European health care systems;
■  Journal articles, i.e., exclusion of books, HTA reports, grey literature;
■  Published between 1995–2005.Cost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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because they were not applied studies or not full evalua-
tions.
Studies analyzed in phase 1 of the review
In summary, 195 articles were included in phase 1 of this
systematic review. The majority of the studies included
were published in English language (95%) and concerned
the health care systems of the United Kingdom (21%) or
the USA (37%). Half of the studies (45%) were published
during 1995–2000 compared to 107 studies (55%) pub-
lished in the 2001–2005 period. In what follows we
describe and briefly discuss the main characteristics of the
studies included.
Category of primary prevention
Looking at the characteristics of the studies concerning the
prevention category they are evaluating, it is obvious that
the vast majority of studies (87%) evaluated measures of
clinical prevention, and pharmacotherapy in particular
(56%) (Table 2). Only a minority of the studies (10%)
examined health promotion activities addressing the
health behaviour of communities of people including
education, advertising, or legislation. Screening for risk
factors for cardiovascular disease was only assessed in a
small fraction of studies (3%), all published between
2001–2005.
Intervention targets
Analyzing the studies included in this review in terms of
the intervention targets, i.e., the risk factors, they exam-
ined, 33% of the 195 evaluations addressed dyslipidemia,
21% targeted smoking and 13% concerned high blood
pressure (Table 3). Only small fractions of the published
studies evaluated interventions targeted at high blood glu-
cose levels (7%), obesity (5%) or dietary intake (6%).
There were significant differences in the targeted risk fac-
tors between study settings: North American studies were
more likely to evaluate the economics of interventions
addressing smoking, dietary intake and dyslipidemia,
while studies assessing interventions within a European
context more often addressed high blood pressure and
glucose levels.
Age of target population
We used the data presented in the original publications to
extract either age-related inclusion criteria or descriptions
of the study sample. Due to this generalized post-hoc clas-
sification, evaluations may cover multiple age groups (e.g.
"25 to 34" and "35 to 44"). Unfortunately, a significant
number of evaluations (19%) did not clearly document
the age of patients included in their study. As can be seen
from the distribution of covered or targeted age groups
(figure 2), the vast majority of studies included subjects
aged 35–64 years in their studies. Many evaluations
assessed health care delivered to seniors: The health of
persons aged 65–74 and 75 and above was addressed in
60% and 39% of studies respectively. Contrary, only very
few studies evaluate interventions targeted at children (0
to 18 years) or young adults (18 to 35 years).
Economic evaluation methods
Of the reviewed studies, the vast majority were cost-effec-
tiveness-analyses that had used "life years gained" (37%)
or clinical outcome measures (e.g., number of avoided
CVD incidents) as benefit measure (27%) (Table 4). A rel-
atively high number of publications (11%) reported no
"true" economic evaluations but observational studies
with information on costs that left health outcomes disag-
gregated and used no summary measure of benefit (cost-
consequence analyses). Comparing changes in the chosen
analytic frameworks over time, a systematic trend towards
more comprehensive methods can be seen. The number
of cost-utility analyses increased significantly from 6 pub-
lished in the period from 1995–2000 (7%) to 32 studies
(30%) published during 2001–2005 (p = <.001). During
the same period there was a slight decrease of cost-effec-
tiveness studies using "life years gained" as measure of
benefit (47% in 1995–2000 vs. 30% in 2001–2005, p =
.017).
Study perspective
The perspective adopted in an economic evaluation can
heavily influence its results and clear reporting of perspec-
tive is therefore crucial. However, in only 59% of the stud-
ies included in the main sample, the authors explicitly
documented the perspective the study was undertaken
from. This fraction increased only slightly over time and
did not differ significantly among study settings. The
majority of evaluations reporting study perspective were
undertaken from the viewpoint of a third party payer
(34%). Among the studies that claimed to be undertaken
from the more comprehensive societal point of view, 13
were cost-utility analyses and 18 cost-effectiveness analy-
ses with "life years gained" as benefit measure.
Funding
Only 64% of evaluations provided provided statements
on funding. Among those, financial support by the indus-
try (26%) and by government (26%) were most frequent
(Table 4). Sponsorship was strongly associated with the
intervention type: Among the studies that reported fund-
ing by the industry, 89% evaluated pharmaceutical inter-
ventions. By contrast, 86% of those studies that disclosed
funding information and evaluated health promotion
activities received governmental grants. The source of
funding was also related to measures of benefit and docu-
mented study perspective in the reviewed studies: evalua-
tions that reported governmental financial support were
more likely to express interventions' outcomes in terms of
more comprehensive benefit measures (QALYs, DALYs,Cost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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"life years gained", or "willingness to pay") (77%), while
industry sponsored studies used comprehensive measures
in only 47% of cases and were more likely to express ben-
efits in terms of fragmented natural units (53%). Industry-
funded evaluations that documented study perspective
were significantly less likely to adopt a societal perspective
as compared to studies financed by government (12% vs.
53%, p = <.001).
Studies analyzed in phase 2 of the review
Of the 195 articles included in phase 1, 35 studies (18%)
evaluated interventions targeted at dietary intake, weight
management, or physical activity, either exclusively or in
a multifaceted approach with other risk factors, and thus
built the sub-sample for the more in depth phase 2 of this
review. Of the 35 studies, 17 (49%) evaluated prevention
in a US or Canadian setting, and 17 studies (49%) were
Overview of in- and exclusion of studies Figure 1
Overview of in- and exclusion of studies.
Identified articles 
(n=5482)
Excluded (n=4898), due to 
 - duplicates (n=3218)
 - violation of basic criteria (n=1680)
Initial inclusion
(n=584)
Fulltext retrieval for
critical appraisal
(n=584)
Dropped after critical appraisal
(n=383)
PHASE 1:
Included evaluations
(n=195)
PHASE 2:
Included evaluations
(n=35)
Fulltext unavailable
(n=6)Cost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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related to European health care systems. One study used a
multinational approach.
Looking at the type of intervention evaluated in the stud-
ies, 74% (n = 26) assessed clinical prevention efforts and
26% (n = 9) evaluated health promotion activities. Evalu-
ated interventions most commonly addressed dietary
intake (n = 12), obesity (n = 10) or various risk factors (n
= 7). The time horizons chosen for the evaluations
showed a variety of 13 alternatives ranging from as short
as "4 month" to a "lifetime" framework. Concerning the
methods utilized to handle uncertainty in parameter esti-
mates, 29% (n = 10) did not document use of sensitivity
analysis, 20% (n = 7) used one-way and 40% (n = 14)
multi-way analysis sensitivity. 11% (n = 4) employed
probabilistic analysis. Out of the subsample of phase 2,
only 13 studies reported incremental cost-effectiveness
ratios.
While the original ambition may have been to compare
the studies included in the sub-sample in order to propose
a ranking of "best buys" in primary prevention, the diver-
sity in the methods and data used to evaluate interven-
tions prevents literal comparison of the resulting cost-
effectiveness ratios. (Nevertheless, to provide a resource
for other researchers and interested parties, the detailed
tabulation of the data extracted from the 35 studies in
Appendix 2 includes these criteria.) The use of compre-
hensive benefit measures is generally far better suited to
enable a comparison of different interventions. Unfortu-
nately, only 20 of the studies included in our phase 2 sub-
sample (57%) used at least one comprehensive benefit
measurement, such as QALYs, DALYs, "life years gained",
or a monetary value – reflecting the findings obtained for
the larger and less-restricted sample in phase 1. The
remainder of the studies used specific clinical parameters
as outcome measures (43%), such as the change in blood
lipid levels, weight loss or behavioural change, making it
almost impossible to weigh studies against each other or
even to estimate the relevance of their associated benefits.
Besides this "unit" difference, other differences in the
methods lead to problems in comparing the studies
among each other. Below we elaborate on just two of
them – the type of costs to include and the discounting
procedure.
Table 2: Interventions by prevention category
Overall (n = 195)
No. (%) of studies
% of studies within category
Health Promotion 20 (10) 100
Education 7 (4) 35
Advertising 4 (2) 20
Legislation 8 (4) 40
Other Health Promotion* 1 (1) 5
Screening 5 (3) 100
Clinical Prevention 170 (87) 100
Health Education 35 (18) 21
Pharmacotherapy 110 (56) 65
Surgery 1 (0.4) 1
Practitioner Education 13 (7) 8
Screening and Clinical Intervention 11 (6) 7
* Summarized over extracted categories
Table 3: Intervention targets by study setting
North America
No. (%) of studies
Europe
No. (%) of studies
Total
No. (%) of studies
Intervention target evaluated
Smoking 24 (28) 16 (16) 40 (22)
Obesity 5 (6) 5 (5) 10 (6)
Physical inactivity 2 (2) 3 (3) 5 (3)
Dietary intake 8 (10) 4 (5) 12 (7)
Dyslipidemia 30 (35) 26 (27) 56 (31)
High blood pressure 6 (7) 18 (18) 24 (13)
High blood glucose levels 3 (4) 10 (10) 13 (7)
Atrial fibrillation 1 (1) 2 (2) 3 (2)
Various 6 (7) 14 (14) 20 (11)Cost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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Type of costs
The studies included in our review show large variability
in the type of costs included. 34 out of 35 studies analyzed
in the subsample included "direct" costs into their calcu-
lation. Only 9 studies also included "productivity losses"
(often termed "indirect costs") in their assessment of
costs. The vast majority of these studies used the "human
capital approach" to value productivity losses. 43% of the
studies (n = 15) also incorporated future cost savings into
their evaluation, while only 9% (n = 3) did include future
costs caused by the additional consumption of medical
goods due to enhanced life expectancy. Obviously, such
diversity seriously impedes any direct comparison of the
studies included, all the more so because the pricing of
units of resources (e.g., doctor consultations) also varies
with the chosen perspective of the analysis (e.g., patient,
society, etc.).
Discounting
The way in which future costs and benefits of an interven-
tion are being discounted, i.e., adjusted for different tim-
ing of costs and benefits and transformed to their 'present
value', greatly influences the economic evaluation of a
given intervention [8]. The higher the discount rate or the
further ahead in the future the cost/benefit, the lower the
net present value of the monetary figures. A glance at
Table 5 confirms that the 35 studies assessed in phase 2
have used very different approaches to discounting:
Nearly every second study (43%) did not apply any dis-
counting to their results. Of those studies that inflated
both costs and benefits (46%), the vast majority used
identical discount rates for both all costs and all benefits.
A discount rate of 3% was most common both for costs
and benefits. As mentioned above, in one study the dis-
count rate differed even by the type of intervention evalu-
Age of target population in included studies, as stated by authors Figure 2
Age of target population in included studies, as stated by authors.
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ated: the benefits of pharmacotherapy with statins were
discounted at a rate of 6% (to take into account side-
effects), while the effects of diet were discounted at a rate
of only 3%.
Conclusion
The purpose of this article has been to examine the main
characteristics of the existing evidence regarding eco-
nomic evaluations of primary prevention, here specifi-
cally applied to CVD event and risk reduction. The
broader policy relevance of this issue is obvious: the allo-
cation of public and private resources overwhelmingly
favours curative interventions as opposed to prevention.
This is for instance illustrated by the 3.2% share out of
government health expenditures that went into the cate-
gory 'prevention and public health' in the 19 OECD coun-
tries for which recent data was available [9]. Taking this
data literally (which is problematic given the challenge of
measuring expenditures on prevention), it is tempting to
infer that these spending levels reflect a sub-optimal level
of prevention, from a social welfare perspective [10].
Assuming this is the case, we hypothesised that a lack of
evidence demonstrating "returns on investment" in pre-
vention may have contributed to the low priority assigned
to it. Our results suggest that a significant amount of eco-
nomic evidence in favour of prevention does exist. How-
ever, at the same time there are important gaps in the
published literature that call for more research.
The majority of the 194 reviewed studies were cost-effec-
tiveness analyses that express benefits as "life years
gained", were conducted in a US or UK setting, assessed
clinical prevention (mainly drugs targeted at lowering
lipid levels), and referred to subjects aged 35–64 years old
with at least one risk factor. The main gaps or limitations
in the reviewed studies, and of the review method per se,
were:
- Only very few studies assessed broader health promotion
interventions targeted at obesity, physical inactivity or
dietary intake in children or young adults.
- Interventions targeting children or young people have
only very rarely been evaluated in economic terms,
despite the high expected benefits that is generally attrib-
uted to "early" prevention.
- The comparability of results between studies is severely
limited by the marked differences in the methodologies
and definitions applied.
The relative lack of broader health promotion evidence we
report does not imply that there was no economic evi-
dence in its favour, if we take the reviewed studies literally.
One relatively strong area of evidence relates to smoking
prevention, in particular to smoking cessation and taxa-
tion- issues that have deliberately not been analysed in
Table 4: Characteristics of economic evaluations by publication period
1995–2000 (n = 88)
No. (%) of studies
2001–2005 (n = 107)
No. (%) of studies
1995–2005 (n = 195)
No. (%) of studies
By Study Type
Cost effectiveness (life years 
gained)
41 (47) 32 (30) 73 (37)
Cost effectiveness (clinical 
outcome)
25 (28) 28 (26) 53 (27)
Cost utility 6 (7) 32 (30) 38 (20)
Cost consequence 11 (13) 10 (9) 21 (11)
Cost minimization 4 (5) 3 (3) 7 (4)
Cost benefit 1 (1) 2 (2) 3 (2)
By Perspective
Societal 15 (17) 23 (22) 38 (20)
Third Party Payer 28 (32) 38 (36) 66 (34)
Health care provider 1 (1) 3 (3) 4 (2)
Patient 1 (1) 1 (1) 2 (1)
Other* 3 (3) 1 (1) 4 (2)
Not stated 40 (46) 41 (38) 81 (42)
By Funding source
Government 20 (23) 31 (29) 51 (26)
Industry 22 (25) 29 (27) 51 (26)
Foundation 10 (11) 5 (5) 15 (8)
Other* 0 (0) 7 (7) 7 (4)
Not stated 36 (41) 35 (33) 71 (36)
* Summarized over extracted categoriesCost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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depth here, because they have been addressed elsewhere
[11,12]. To quote but one study from our sample in Phase
I, Wang et al. [13] demonstrate that a project to prevent
tobacco use among school children has proved to be even
cost-saving. Importantly, this is also one of the very few
studies explicitly targeting adolescents.
Compared to smoking – a comparatively "old" challenge
– it is not surprising that thus far significantly less (cost-
)effectiveness evidence has been accumulated in terms of
the prevention of dietary intake and obesity. The most
comprehensive study – when judged by the set of inter-
ventions covered – demonstrated remarkably favourable
cost-effectiveness evidence for a number of such interven-
tions, e.g., legislation to reduce salt content in processed
food or broad-based health education [14]. A further
advantage of the same study was that it allowed for an
assessment of various combinations of personal, preven-
tive and curative, as well as non-personal interventions
[14]. This brings the situation analysed much closer to
that faced by public health and health care decision mak-
ers, where the choice is typically not between one inter-
vention and another, but rather between sets of
interventions.
Despite these important contributions, the evidenced bias
on curative, clinical care is in line with the findings of
other studies. Pritchard had earlier examined the charac-
teristics of all economic evaluations included in the HEED
database [15], concluding that only 10% of all evaluations
assessed preventive care. The scarcity of broader public
health interventions in the present review as well as in
other studies may be explained by at least three factors.
(1) The applied formal analytical technique has strong
requirements that may be less amenable to assessing
"broader" types of interventions. (2) Economic evalua-
tions are often conducted as a necessary condition for cov-
erage by statutory health insurances, and therefore
concentrate on interventions that are – in principle – sub-
ject to coverage, such as pharmaceuticals. Factors that con-
tribute to a healthy living but are traditionally assigned to
individual, private life, such as healthy nutrition, often
lack this "pressure to prove" since there is no administra-
tive institution deciding upon coverage. (3) The fact that
the majority of studies have been financed by the private
industry may in part explain the overrepresentation of
pharmaceutical interventions.
As others, we observed a very high level of variability in
the methods utilized in economic evaluations [4,16,17].
We did not formally address methodological quality or
adherence to established guidelines, and there may be
good reasons for different study designs for different pur-
poses that lack comparability but are all, each by them-
selves, legitimate and in concordance with best practice
recommendations. In addition, differing methodological
approaches do not per se limit comparability as long as
methods are clearly documented and results are presented
in a way that would enable conversion to a common unit.
However, we encountered severe limitations in transpar-
ency and documentation of main study details, e.g., cho-
sen study perspective. In addition, significant numbers of
studies failed to provide details on units of resource con-
sumption, costing year, currencies and other details, as
required by virtually all scientific guidelines on economic
evaluation.
The reviewed evidence as such offers little to settle the
debate on the relative benefits of prevention versus cure.
However, there appear to be certain methodological fea-
tures in the current practice of economic evaluations that
might bias the choice between prevention and cure in
favour of the latter. In this article we have discussed in par-
ticular the issue of the treatment of future costs and the
discounting of future health benefits.
The diversity in the discounting procedures applied in the
reviewed studies does not facilitate the comparison
between the different interventions proposed, and raises
the question whether there exists one "correct" way of dis-
counting costs and benefits. As there is general agreement
on the need for the discounting of costs, the zero dis-
counting rate applied in 15 studies in our sample is deeply
concerning. Still, the scientific debate about how to cor-
rectly treat future health benefits remains unresolved [18].
The debate revolves around several aspects, including the
Table 5: Methodology for discounting in studies (phase 2)
No. (%) of studies 
(n = 35)
Discounting approach
No discounting 15 (43)
Identical discount rates for costs and benefits 14 (40)
Different discount rates for costs and benefits 2 (6)
Only discounting of costs 2 (6)
Only discounting of benefits 2 (6)
Discount rate for costs
0% 17 (49)
3% 11 (31)
5% 5 (14)
6% 2 (6)
Discount rate for benefits
0% 17 (49)
1.5% 1 (3)
3% 11 (31)
5% 5 (14)
6% 1 (3)Cost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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issue of time-varying discount rates to reflect time prefer-
ence [19,20] or discounting models in relation to effec-
tiveness measures [21], but the core controversy centres
mainly on whether the health benefits of a given interven-
tion should be discounted at a lower rate than the costs or
at the same, uniform rate [22,23].
Whatever the "correct" way of discounting is – a question
we cannot address properly here -the current predomi-
nant practice of uniform discounting does have implica-
tions for the choice between prevention versus cure at
large. Since in the case of prevention health benefits tend
to occur further ahead in the future compared to treat-
ment, uniform discounting leads to the prioritization of
immediate treatment at the expense of prevention. Differ-
ential discounting, with discount rates for health benefits
lower than for costs, would certainly devalue future health
benefits by much less than uniform discounting does. As
a result, prevention would appear more favourable than it
presently seems in economic evaluations. (Clearly, also
the level of the uniform discount rate per se critically
affects the choice between prevention and cure.) Simi-
larly, the introduction of variable (but uniform) discount
rates over time could lead to a greater appreciation of the
benefits of prevention. [24-27].
Similar conclusions can be drawn from our findings relat-
ing to the inclusion of future costs: we found a high level
of variability in the extent to which future costs are
included in economic evaluations which is not suprising
since guidelines rarely provide clear recommendations
[28]. The question which costs to consider in the assess-
ment of interventions has important and systematic con-
sequences for their demonstrated favourability, and, as
such, a high potential for introducing bias towards spe-
cific areas of care [29-32]. The in- or exclusion of future
costs and savings due to related illness and "unrelated" ill-
nesses is of particular relevance for the evaluation of pre-
vention. Van Baal et al. exemplified the effects of
including future costs of unrelated illnesses by computing
different cost-utility ratios for smoking cessation interven-
tions in different age groups [33]. Including health care
costs of unrelated medical care in life years gained
increased ratios, but excluding unrelated medical costs
favoured smoking cessation interventions targeted at
older smokers over those at younger smokers. They con-
clude that for primary prevention only a cost utility ratio
that includes both the costs and effects of unrelated med-
ical care meets the criterion of internal consistency. From
a pro-preventive perspective, the common practice of
excluding future costs may bias cost-effectiveness analyses
against such interventions, and, within such interven-
tions, against younger age groups.
In interpreting the above findings, the limitations of our
study need to be borne in mind [34]:
(1) We limited our search to specific databases, year
ranges and publication media and a number of tight
inclusion criteria were pre-specified. Thus we cannot rule
out having overlooked important evidence, for instance
from the grey literature.
(2) We did not restrict our sample to single countries or
small geographic domains but included studies applied to
North American and European countries. While this
approach is valuable in describing the available evidence
from a meta perspective, it limits the use of our results for
health policy and decision making due to a lack of gener-
alizability of health economic data across countries [35].
(3) As is characteristic of systematic reviews in general, we
were only able to identify, review and summarize what has
been published, instead of what has not been published. The
fact that studies that do not prove what has been expected
by researchers (or funding parties) are less likely to get
published introduces systematic bias, known as "publica-
tion bias". Hence, studies that report favourable results
are overrepresented and there is a tendency to overesti-
mate efficiency and effectiveness of health care interven-
tions. The phenomenon of "publication" bias has been
well described for the biomedical literature and has been
identified as a major threat to reliable syntheses of out-
comes research [36-40]. Economic analyses is even more
vulnerable to publication bias [41].
The relative scarcity of economic evaluations of broader
health promotion interventions has implications far
beyond the merely scientific ones: in a situation that has
essentially all high-income countries and increasingly also
the developing world grappling with the mounting chal-
lenge of obesity and other "lifestyle-related diseases".
There is reason to doubt as to whether clinical interven-
tion will be the most effective (or even cost-effective) way
to tackle challenges of this kind. Yet, as public budgets are
tightening as the result of demographic and technological
change, proving value for money arguably is becoming
ever more important to justify investment at the policy
level.
How can the existing evidence gaps be closed? Above all,
there is a strong efficiency case for an increased public role
in the promotion and production of evidence on primary
prevention [10]. First, this would serve filling the gap left
by private industry in terms of the evaluation of broader
public health interventions and health promotion. In
addition, it could contribute to a less biased representa-
tion of the clinical prevention results, given the docu-
mented relationship between study funding and reportingCost Effectiveness and Resource Allocation 2007, 5:5 http://www.resource-allocation.com/content/5/1/5
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of favourable results [42-46]. Given the diversity of
approaches witnessed even within the smaller sample of
studies analysed, a key component in the development of
"better", i.e., more comparable evaluations should be a
greater adherence to established guidelines on economic
evaluation including, above all, a higher level of transpar-
ency in the applied methods.
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